Analysts Set Centessa Pharmaceuticals plc (NASDAQ:CNTA) Target Price at $10.00

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has earned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $10.50.

Several research firms recently commented on CNTA. BMO Capital Markets reiterated an “outperform” rating and set a $15.00 price objective on shares of Centessa Pharmaceuticals in a research note on Monday, April 1st. Morgan Stanley boosted their price objective on shares of Centessa Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Friday.

Centessa Pharmaceuticals Trading Up 2.7 %

NASDAQ:CNTA opened at $9.10 on Friday. Centessa Pharmaceuticals has a one year low of $5.15 and a one year high of $12.45. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.37 and a current ratio of 10.37. The firm has a market cap of $914.37 million, a P/E ratio of -6.58 and a beta of 1.39. The firm has a 50-day simple moving average of $9.22 and a 200-day simple moving average of $9.18.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.03. Equities analysts anticipate that Centessa Pharmaceuticals will post -1.71 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Karen M. Anderson sold 51,160 shares of the stock in a transaction on Monday, March 25th. The shares were sold at an average price of $11.88, for a total transaction of $607,780.80. Following the sale, the insider now directly owns 71,525 shares of the company’s stock, valued at $849,717. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 11.59% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in CNTA. First Light Asset Management LLC acquired a new position in Centessa Pharmaceuticals during the first quarter worth $33,923,000. Octagon Capital Advisors LP raised its position in Centessa Pharmaceuticals by 333.2% during the fourth quarter. Octagon Capital Advisors LP now owns 2,060,100 shares of the company’s stock worth $16,398,000 after acquiring an additional 1,584,500 shares during the period. Adage Capital Partners GP L.L.C. raised its position in Centessa Pharmaceuticals by 25.8% during the third quarter. Adage Capital Partners GP L.L.C. now owns 2,830,500 shares of the company’s stock worth $18,313,000 after acquiring an additional 580,500 shares during the period. Price T Rowe Associates Inc. MD raised its position in Centessa Pharmaceuticals by 16.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock worth $33,427,000 after acquiring an additional 418,615 shares during the period. Finally, Artal Group S.A. raised its position in Centessa Pharmaceuticals by 39.5% during the first quarter. Artal Group S.A. now owns 1,412,500 shares of the company’s stock worth $15,961,000 after acquiring an additional 400,000 shares during the period. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.